U.S. FDA Cancels Telavancin Advisory Panel Review 3 Days Before Meeting
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA cancelled a Feb. 27 advisory panel meeting for Astellas Pharma/Theravance's telavancin to allow the agency time "to review and resolve several outstanding issues" in the NDA, the agency said Feb. 25